Median CD4 count (cells/µl) and interquartile range, from ART initiation in the HIV-2 cohort, IeDEA West Africa collaboration.

Tornado diagram of one-way sensitivity analyses when ART-eligibility threshold is at CD4 count ≤250/µl.

A range of parameters varied in one-way sensitivity analyses are displayed on the vertical axis.

Effects, cost, and cost-effectiveness of universal test and treat versus continued scale-up of ART at CD4 count ≤350 cells/µl in South Africa over the period 2012–2050 (Model D).

Costs and effects are discounted at an annual rate of 3%. Life-years concern the total life-years

SHIMS CD4 Count Cohort (Cohort C)

Swaziland HIV Incidence Measurement Survey CD4 count cohort dataset

Cumulative net costs and cumulative number of life-years saved of universal testing and immediate ART for all HIV-infected patients (UTT) compared to the current rollout in South Africa of ART at CD4 count ≤350 cells/µl, as predicted with model D.

(A) Cumulative net costs; (B) cumulative number of life-years saved. Grey lines represent 100 ind

CD4+ cell count recovery following initiation of HIV antiretroviral therapy in older childhood and adolescence

Objective

To investigate CD4þ cell count recovery following ART initiation in perinatal

Mortality and losses to follow-up among adolescents living with HIV in the IeDEA global cohort collaboration

International audience INTRODUCTION: We assessed mortality and losses to follow-up (L